{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:30:35Z","timestamp":1793118635574,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T00:00:00Z","timestamp":1532649600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40273-018-0688-4","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T03:34:46Z","timestamp":1532662486000},"page":"1285-1296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Sacubitril\/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4262-8344","authenticated-orcid":false,"given":"Afschin","family":"Gandjour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Ostwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,27]]},"reference":[{"issue":"8","key":"688_CR1","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s00392-015-0841-4","volume":"104","author":"C Ohlmeier","year":"2015","unstructured":"Ohlmeier C, Mikolajczyk R, Frick J, Pr\u00fctz F, Haverkamp W, Garbe E. Incidence, prevalence and 1-year all-cause mortality of heart failure in Germany: a study based on electronic healthcare data of more than six million persons. Clin Res Cardiol. 2015;104(8):688\u201396.","journal-title":"Clin Res Cardiol"},{"issue":"11","key":"688_CR2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00392-017-1137-7","volume":"106","author":"S St\u00f6rk","year":"2017","unstructured":"St\u00f6rk S, Handrock R, Jacob J, Walker J, Calado F, Lahoz R, Hupfer S, Klebs S. Epidemiology of heart failure in Germany: a retrospective database study. Clin Res Cardiol. 2017;106(11):913\u201322.","journal-title":"Clin Res Cardiol"},{"issue":"19","key":"688_CR3","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","volume":"34","author":"SJ Pocock","year":"2013","unstructured":"Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, K\u00f8ber L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN, Meta-Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013;34(19):1404\u201313.","journal-title":"Eur Heart J"},{"key":"688_CR4","volume-title":"Krankheitskostenrechnung","author":"Statistisches Bundesamt","year":"2015","unstructured":"Bundesamt Statistisches. Krankheitskostenrechnung. Wiesbaden: Statistisches Bundesamt; 2015."},{"issue":"11","key":"688_CR5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K. Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"issue":"1","key":"688_CR6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","volume":"131","author":"M Packer","year":"2015","unstructured":"Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, B\u011blohl\u00e1vek J, B\u00f6hm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonz\u00e0lez-Medina A, Hag\u00e8ge AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan \u00d6, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D. Wong RC, PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54\u201361.","journal-title":"Circulation"},{"issue":"11","key":"688_CR7","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/1060028015593093","volume":"49","author":"MP Lillyblad","year":"2015","unstructured":"Lillyblad MP. Dual angiotensin receptor and neprilysin inhibition with sacubitril\/valsartan in chronic systolic heart failure: understanding the New PARADIGM. Ann Pharmacother. 2015;49(11):1237\u201351.","journal-title":"Ann Pharmacother"},{"issue":"19","key":"688_CR8","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jacc.2015.08.878","volume":"66","author":"J Simpson","year":"2015","unstructured":"Simpson J, Jhund PS, Silva Cardoso J, Martinez F, Mosterd A, Ramires F, Rizkala AR, Senni M, Squire I, Gong J, Lefkowitz MP, Shi VC, Desai AS, Rouleau JL, Swedberg K, Zile MR, McMurray JJ, Packer M. Solomon SD, PARADIGM-HF Investigators and Committees. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF Risk Scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol. 2015;66(19):2059\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"688_CR9","unstructured":"Novartis Pharma GmbH. Sacubitril\/Valsartan (Entresto\u00ae): Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V (Modul 4 A). \n                    https:\/\/www.g-ba.de\/downloads\/92-975-1312\/2015-12-21_Modul4A_Sacubitril-Valsartan.pdf\n                    \n                  . Accessed 13 June 2018."},{"issue":"18","key":"688_CR10","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","volume":"273","author":"R Garg","year":"1995","unstructured":"Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273(18):1450\u20136.","journal-title":"JAMA"},{"key":"688_CR11","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. General methods. Version 5.0. K\u00f6ln: IQWiG. 2017."},{"issue":"23","key":"688_CR12","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMc1509753","volume":"373","author":"B Claggett","year":"2015","unstructured":"Claggett B, Packer M, McMurray JJ, Swedberg K, Rouleau J, Zile MR, Jhund P, Lefkowitz M, Shi V, Solomon SD, PARADIGM-HF Investigators. Estimating the long-term treatment benefits of sacubitril-valsartan. N Engl J Med. 2015;373(23):2289\u201390.","journal-title":"N Engl J Med"},{"key":"688_CR13","unstructured":"Lauer-Fischer GmbH, Lauer-Taxe Arzneimittelpreise. \n                    https:\/\/www.lauer-fischer.de\n                    \n                  . Accessed 30 June 2018"},{"issue":"8","key":"688_CR14","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s10198-015-0744-3","volume":"17","author":"KE Fischer","year":"2016","unstructured":"Fischer KE, Stargardt T. The diffusion of generics after patent expiry in Germany. Eur J Health Econ. 2016;17(8):1027\u201340.","journal-title":"Eur J Health Econ."},{"key":"688_CR15","unstructured":"Kassen\u00e4rztliche Bundesvereinigung. Einheitlicher Bewertungsma\u00dfstab (EBM). Stand: 1. Quartal 2015. Berlin: Kassen\u00e4rztliche Bundesvereinigung; 2018."},{"key":"688_CR16","volume-title":"Fallpauschalen-Katalog 2015","author":"Institut f\u00fcr das Entgeltsystem im Krankenhaus","year":"2018","unstructured":"Institut f\u00fcr das Entgeltsystem im Krankenhaus. Fallpauschalen-Katalog 2015. Siegburg: InEK GmbH; 2018."},{"key":"688_CR17","unstructured":"Management Consult Kestermann (2015). Gutachten zur ambulanten Notfallversorgung im Krankenhaus: Fallkostenkalkulation und Strukturanalyse. \n                    http:\/\/www.dkgev.de\/media\/file\/19401.2015-02-17_Gutachten_zur_ambulanten_Notfallversorgung_im_Krankenhaus_2015.pdf\n                    \n                  . Accessed 29 May 2018."},{"key":"688_CR18","volume-title":"Krankheitskostenrechnung","author":"Statistisches Bundesamt","year":"2010","unstructured":"Bundesamt Statistisches. Krankheitskostenrechnung. Bonn: Statistisches Bundesamt; 2010."},{"issue":"Suppl 1","key":"688_CR19","first-page":"P3373","volume":"38","author":"D Trueman","year":"2017","unstructured":"Trueman D, Kapetanakis V, Briggs A, Lewis E, Rouleau J, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV, Croft DC, Haroun R, Gielen V. Better health-related quality of life in patients treated with sacubitril\/valsartan compared with enalapril, irrespective of NYHA class: Analysis of EQ-5D in PARADIGM-HF. Eur Heart J. 2017;38(Suppl 1):P3373.","journal-title":"Eur Heart J"},{"key":"688_CR20","unstructured":"Novartis Pharma GmbH. Sacubitril\/Valsartan (Entresto\u00ae): Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V (Modul 3 A). \n                    https:\/\/www.g-ba.de\/downloads\/92-975-1311\/2015-12-21_Modul3A_Sacubitril-Valsartan.pdf\n                    \n                  . Accessed 29 May 2018."},{"issue":"38","key":"688_CR21","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","volume":"36","author":"PS Jhund","year":"2015","unstructured":"Jhund PS, Fu M, Bayram E, Chen CH, Negrusz-Kawecka M, Rosenthal A, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M, PARADIGM-HF Investigators and Committees. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015;36(38):2576\u201384.","journal-title":"Eur Heart J"},{"issue":"3","key":"688_CR22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","journal-title":"Health Policy"},{"issue":"4","key":"688_CR23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1177\/0272989X09340585","volume":"29","author":"JJ Barendregt","year":"2009","unstructured":"Barendregt JJ. The half-cycle correction: banish rather than explain it. Med Decis Mak. 2009;29(4):500\u20132.","journal-title":"Med Decis Mak."},{"key":"688_CR24","volume-title":"Allgemeine Sterbetafel 2010\/12","author":"Statistisches Bundesamt","year":"2015","unstructured":"Bundesamt Statistisches. Allgemeine Sterbetafel 2010\/12. Wiesbaden: Statistisches Bundesamt; 2015."},{"key":"688_CR25","volume-title":"Economic evaluation in health care: merging theory with practice","author":"K Kuntz","year":"2001","unstructured":"Kuntz K, Weinstein M. Modelling in economic evaluation. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press; 2001."},{"key":"688_CR26","volume-title":"Bev\u00f6lkerung: Deutschland, Stichtag, Altersjahre","author":"Statistisches Bundesamt","year":"2015","unstructured":"Bundesamt Statistisches. Bev\u00f6lkerung: Deutschland, Stichtag, Altersjahre. Wiesbaden: Statistisches Bundesamt; 2015."},{"key":"688_CR27","volume-title":"Bev\u00f6lkerung Deutschlands bis 2060 \u2013 13. koordinierte Bev\u00f6lkerungsvorausberechnung","author":"Statistisches Bundesamt","year":"2010","unstructured":"Statistisches Bundesamt. Bev\u00f6lkerung Deutschlands bis 2060 \u2013 13. koordinierte Bev\u00f6lkerungsvorausberechnung. Wiesbaden: Statistisches Bundesamt; 2010."},{"key":"688_CR28","first-page":"168","volume-title":"Human mortality beyond age 110. In Supercentenarians","author":"J Gampe","year":"2010","unstructured":"Gampe J. Human mortality beyond age 110. In Supercentenarians. Berlin: Springer; 2010. p. 168\u2013230."},{"issue":"5","key":"688_CR29","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.pcad.2005.02.010","volume":"47","author":"TE Owan","year":"2005","unstructured":"Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis. 2005;47(5):320\u201332.","journal-title":"Prog Cardiovasc Dis."},{"issue":"1","key":"688_CR30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejheart.2006.10.012","volume":"9","author":"EF Lewis","year":"2007","unstructured":"Lewis EF, Lamas GA, O\u2019Meara E, Granger CB, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Halling K, Carlsson J, Olofsson B, McMurray JJ, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. 2007;9(1):83\u201391.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"688_CR31","doi-asserted-by":"crossref","first-page":"e59225","DOI":"10.1371\/journal.pone.0059225","volume":"8","author":"D Tiller","year":"2013","unstructured":"Tiller D, Russ M, Greiser KH, Nuding S, Ebelt H, Kluttig A, Kors JA, Thiery J, Bruegel M, Haerting J, Werdan K. Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population-the CARLA study. PLoS One. 2013;8(3):e59225.","journal-title":"PLoS One"},{"issue":"6","key":"688_CR32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1055\/s-0041-101017","volume":"140","author":"R Wachter","year":"2015","unstructured":"Wachter R. Diastolic heart failure and multimorbidity. Dtsch Med Wochenschr. 2015;140(6):402\u20135.","journal-title":"Dtsch Med Wochenschr"},{"key":"688_CR33","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5771\/9783845287997","volume-title":"AMNOG-Check 2017: Gesundheits\u00f6konomische Analysen der Versorgung mit Arzneimittel-Innovationen","author":"D Cassel","year":"2017","unstructured":"Cassel D, Ulrich V. AMNOG-Check 2017: Gesundheits\u00f6konomische Analysen der Versorgung mit Arzneimittel-Innovationen. Baden-Baden: Nomos Verlagsgesellschaft; 2017. p. 168."},{"issue":"22","key":"688_CR34","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2018.01.085","volume":"71","author":"MA Cavender","year":"2018","unstructured":"Cavender MA, Norhammar A, Birkeland KI, J\u00f8rgensen ME, Wilding JP, Khunti K, Fu AZ, Bodeg\u00e5rd J. Blak BT, Wittbrodt E, Thuresson M, Fenici P, Hammar N, Kosiborod M, CVD-REAL Investigators and StudyGroup. SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. J Am Coll Cardiol. 2018;71(22):2497\u2013506.","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"688_CR35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, Orlewska E, Penna P, Rodriguez Barrios JM, Shau WY. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5\u201314.","journal-title":"Value Health."},{"issue":"2","key":"688_CR36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00392-007-0586-9","volume":"97","author":"P Aidelsburger","year":"2008","unstructured":"Aidelsburger P, Grabein K, Klauss V, Wasem J. Cost-effectiveness of cardiac resynchronization therapy in combination with an implantable cardioverter defibrillator (CRT-D) for the treatment of chronic heart failure from a German health care system perspective. Clin Res Cardiol. 2008;97(2):89\u201397.","journal-title":"Clin Res Cardiol"},{"issue":"6","key":"688_CR37","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jval.2011.02.1180","volume":"14","author":"A Gandjour","year":"2011","unstructured":"Gandjour A, Holler A, Adarkwah CC. Cost-effectiveness of implantable defibrillators after myocardial infarction based on 8-year follow-up data (MADIT II). Value Health. 2011;14(6):812\u20137.","journal-title":"Value Health."},{"issue":"10","key":"688_CR38","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/M16-0057","volume":"165","author":"AT Sandhu","year":"2016","unstructured":"Sandhu AT, Ollendorf DA, Chapman RH, Pearson SD, Heidenreich PA. Cost-effectiveness of sacubitril-valsartan in patients with heart failure with reduced ejection fraction. Ann Intern Med. 2016 Nov 15;165(10):681\u20139.","journal-title":"Ann Intern Med"},{"issue":"6","key":"688_CR39","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","volume":"1","author":"TA Gaziano","year":"2016","unstructured":"Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, Rouleau JL, Zile MR, McMurray JJ, Solomon SD. Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol. 2016;1(6):666\u201372.","journal-title":"JAMA Cardiol."},{"issue":"5","key":"688_CR40","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jchf.2016.02.007","volume":"4","author":"JB King","year":"2016","unstructured":"King JB, Shah RU, Bress AP, Nelson RE, Bellows BK. Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2016;4(5):392\u2013402.","journal-title":"JACC Heart Fail."},{"issue":"3","key":"688_CR41","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jval.2016.10.015","volume":"20","author":"S Pol van der","year":"2017","unstructured":"van der Pol S, Degener F, Postma MJ, Vemer P. An economic evaluation of sacubitril\/valsartan for heart failure patients in the Netherlands. Value Health. 2017;20(3):388\u201396.","journal-title":"Value Health."},{"issue":"10","key":"688_CR42","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.jval.2017.05.013","volume":"20","author":"I Corro Ramos","year":"2017","unstructured":"Corro Ramos I, Versteegh MM, de Boer RA, Koenders JM, Linssen GC, Meeder JG, Rutten-van M\u00f6lken MP. Cost-effectiveness of the angiotensin receptor neprilysin inhibitor sacubitril\/valsartan for patients with chronic heart failure and reduced ejection fraction in the Netherlands: a country adaptation analysis under the former and current Dutch Pharmacoeconomic Guidelines. Value Health. 2017;20(10):1260\u20139.","journal-title":"Value Health."},{"key":"688_CR43","unstructured":"National Institute for Health and Care Excellence. Final appraisal determination: sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction. Issue date: March 2016."},{"key":"688_CR44","volume-title":"Cost-effectiveness in health and medicine","year":"2016","unstructured":"Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost-effectiveness in health and medicine. 2nd ed. New York: Oxford University Press; 2016.","edition":"2"},{"issue":"6","key":"688_CR45","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jval.2016.06.002","volume":"19","author":"SE Grimm","year":"2016","unstructured":"Grimm SE, Dixon S, Stevens JW. When future change matters: modeling future price and diffusion in health technology assessments of medical devices. Value Health. 2016;19(6):720\u20136.","journal-title":"Value Health."},{"issue":"3","key":"688_CR46","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","volume":"6","author":"PA Heidenreich","year":"2013","unstructured":"Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Pi\u00f1a IL, Trogdon JG, American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606\u201319.","journal-title":"Circ Heart Fail."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-018-0688-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0688-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0688-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T21:42:07Z","timestamp":1569102127000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-018-0688-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,27]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["688"],"URL":"https:\/\/doi.org\/10.1007\/s40273-018-0688-4","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,27]]},"assertion":[{"value":"27 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All data generated or analyzed during this study are included in this published article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"This study was funded by Novartis Deutschland GmbH.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}